This revenue range excludes revenue from Lucent Diagnostics testing, which is expected to be immaterial for 2024. The company also reaffirmed that it expects its research-use only business to achieve cash flow breakeven when it reaches revenue between $170M-$190M. The Company continues to expect GAAP gross margin percentage to be in the range of 57%-61%, and non-GAAP gross margin percentage to be in the range of 51%-55%. The company continues to anticipate 2024 cash usage to be approximately $30M.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: